Almirall, S.A. is a Spanish pharmaceutical company dedicated to medical dermatology, with headquarters in Barcelona, founded in 1944.

In 2023, the company generated total revenues of €898.8 million and was the leading European company in medical dermatology.

With approximately 1,904 employees (2023), it has a direct presence in 20 countries through its 15 subsidiaries in Europe and the USA.

Almirall SA was founded in 1944 in Spain. In 1979, the company launched gastroprokinetic clebopride in Spain, the first product from the company’s internal R&D team. In 1984, the business launched antacid product, almagate, in Spain, as well as anti-inflammatory piketoprofen in 1985 and antihistamine ebastine and cinitapride in 1985. In the same year, Almirall opened its first subsidiary, based in Belgium. In 1992 the company launched aceclofenac and a year later opened its second foreign subsidiary, in Portugal. The company's new headquarters were opened in Barcelona, in 1994. In 1997 Almirall and Prodesfarma merged their interests.

In 2000 the FDA approved anti-migraine agent almotriptan. A year later the company opened its Mexican subsidiary as well as acquiring its French affiliate. Beginning in 2002, Almirall opened a series of European based subsidiaries; Italy (2002), Germany (2003), Austria, Poland, the United Kingdom, Ireland and Switzerland (2008), Nordic Countries (2010) and Netherlands (2013).

In 2005 the business acquired the commercial rights for Sativex in Europe for the treatment of spasticity associated to multiple sclerosis. In 2006, the company opened its new R&D Centre based in Sant Feliu de Llobregat as well as the acquisition of the Centre of Excellence for Inhalation Technology.

In 2007, the company floated on the Spanish stock market, as well as acquiring European dermatology specialist, Hermal. The company also acquired a portfolio of eight products from Shire plc.

In 2011, Almirall launched Actikerall prescribed for the local treatment of actinic keratosis.